Afficher la couverture 'Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study | Kim, Min Seo' en grand format
/5

0 avis

Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study

Archive ouverte

Kim, Min Seo | Jung, Se Yong | Lee, Seung Won | Li, Han | Koyanagi, Ai | Kronbichler, Andreas | Dragioti, Elena | Tizaoui, Kalthoum | Wasuwanich, Paul | Hong, Sung Hwi | Ghayda, Ramy Abou | Yoo, Hae Won | Kim, Hanna | Jacob, Louis | Salem, Joe-Elie | Kostev, Karel | Shin, Youn Ho | Kim, So Young | Gamerith, Gabriele | Yon, Dong Keon | Shin, Jae Il | Smith, Lee

Edité par CCSD ; WB Saunders -

International audience. Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19)1-4 and was first approved for COVID-19 patients.5 However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear.1-4,6 Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization's international pharmacovigilance database of individual case safety reports.

Consulter en ligne

Suggestions

Du même auteur

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Archive ouverte | Jung, Se Yong | CCSD

International audience. On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions ...

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Archive ouverte | Jung, Se Yong | CCSD

International audience. On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions ...

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Archive ouverte | Jung, Se Yong | CCSD

International audience. On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions ...

Chargement des enrichissements...